ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
-13.63%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$179M
AUM Growth
+$179M
(-15%)
Cap. Flow
+$5.98M
Cap. Flow
% of AUM
3.35%
Top 10 Holdings %
Top 10 Hldgs %
60.48%
Holding
53
New
12
Increased
12
Reduced
10
Closed
9
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
$4.24M |
| 2 |
Precision BioSciences
DTIL
|
$3.28M |
| 3 |
United Therapeutics
UTHR
|
$3.06M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$2.82M |
| 5 |
Rezolute
RZLT
|
$2.08M |
Top Sells
| 1 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$5.52M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$3.96M |
| 3 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
$2.47M |
| 4 |
Athira Pharma
ATHA
|
$1.89M |
| 5 |
Merus
MRUS
|
$1.85M |
Sector Composition
| 1 | Healthcare | 89.23% |
| 2 | Financials | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $25.1M | 13.96% | 554,000 | – | – |
|
|
WHWK
2
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $18.8M | 10.5% | 1,529,402 | – | – |
|
3
VistaGen Therapeutics
VTGN
$102M
| $10M | 5.57% | 11,361,451 -374,832 | -3% | -$330K |
|
4
Kura Oncology
KURA
$686M
| $9.83M | 5.48% | 536,500 +62,531 | +13% | +$1.15M |
|
|
BLSA
5
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.35M | 4.65% | 843,122 | – | – |
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $8.29M | 4.62% | 272,500 +47,500 | +21% | +$1.44M |
|
|
BLU
7
DELISTED
BELLUS Health Inc.
BLU
| $7.54M | 4.2% | 816,000 | – | – |
|
8
Celldex Therapeutics
CLDX
$1.47B
| $7.2M | 4.01% | 267,195 -55,703 | -17% | -$1.5M |
|
9
Relmada Therapeutics
RLMD
$37.2M
| $6.69M | 3.73% | 352,500 +10,500 | +3% | +$199K |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.34M | 3.53% | 94,500 +42,000 | +80% | +$2.82M |
|
|
JYAC
11
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.55M | 3.09% | 562,500 | – | – |
|
|
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.42M | 3.02% | 563,607 +24,107 | +4% | +$232K |
|
|
13
Arcus Biosciences
RCUS
$1.13B
| $4.24M | 2.36% | +167,500 | New | +$4.24M |
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $3.94M | 2.2% | 205,003 -1,123 | -0.5% | -$21.6K |
|
15
Orchestra BioMed
OBIO
$147M
| $3.91M | 2.18% | 392,500 | – | – |
|
|
16
Merus
MRUS
$4.98B
| $3.49M | 1.94% | 154,000 -81,500 | -35% | -$1.85M |
|
|
17
Precision BioSciences
DTIL
$57.8M
| $3.28M | 1.83% | +2,050,359 | New | +$3.28M |
|
|
18
United Therapeutics
UTHR
$13.8B
| $3.06M | 1.71% | +13,000 | New | +$3.06M |
|
|
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.86M | 1.59% | 35,888 +2,688 | +8% | +$214K |
|
20
Milestone Pharmaceuticals
MIST
$156M
| $2.81M | 1.57% | 457,200 +77,200 | +20% | +$475K |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $2.71M | 1.51% | 234,026 -105,974 | -31% | -$1.23M |
|
22
Aclaris Therapeutics
ACRS
$209M
| $2.69M | 1.5% | 192,835 -24,765 | -11% | -$346K |
|
23
GH Research
GHRS
$837M
| $2.43M | 1.35% | 243,250 -176,382 | -42% | -$1.76M |
|
24
EyePoint Pharmaceuticals
EYPT
$797M
| $2.39M | 1.33% | 303,396 -4,548 | -1% | -$35.8K |
|
25
Arrowhead Research
ARWR
$3.05B
| $2.18M | 1.21% | 61,926 -20,574 | -25% | -$724K |
|